scispace - formally typeset
Journal ArticleDOI

Life expectancy of HIV‐positive people after starting combination antiretroviral therapy: a meta‐analysis

Reads0
Chats0
TLDR
A meta‐analysis was performed to assess life expectancy of HIV‐positive people after starting cART, and to quantify differences between low/middle‐ and high‐income countries.
Abstract
Objectives Life expectancy is an important indicator informing decision making in policies relating to HIV-infected people. Studies estimating life expectancy after starting combination antiretroviral therapy (cART) have noted differences between income regions. The objective of our study was to perform a meta-analysis to assess life expectancy of HIV-positive people after starting cART, and to quantify differences between low/middle- and high-income countries. Methods Eight cohort studies estimating life expectancy in HIV-positive people initiating cART aged ≥ 14 years using the abridged life table method were identified. Random effects meta-analysis was used to pool estimated outcomes, overall and by income region. Heterogeneity between studies was assessed with the I2 statistic. We estimated additional years of life expected after starting cART at ages 20 and 35 years. Results Overall life expectancy in high-income countries was an additional 43.3 years [95% confidence interval (CI) 42.5–44.2 years] and 32.2 years (95% CI 30.9–33.5 years) at ages 20 and 35 years, respectively, and 28.3 (95% CI 23.3–33.3) and 25.6 (95% CI 22.1–29.2) additional years, respectively, in low/middle-income countries. In low/middle-income countries, life expectancy after starting cART at age 20 years was an additional 22.9 years (95% CI 18.4–27.5 years) for men and 33.0 years (95% CI 30.4–35.6 years) for women, but was similar in the two sexes in high-income countries. In all income regions, life expectancy after starting cART increased over calendar time. Conclusions Our results suggest that the life expectancy of HIV-positive people after starting cART has improved over time. Monitoring life expectancy into the future is important to assess how changes to cART guidelines will affect patient long-term outcomes.

read more

Citations
More filters
Journal ArticleDOI

High Virologic Failure Rates with Maraviroc-Based Salvage Regimens Among Indian Patients: A Preliminary Analysis-Maraviroc Effectiveness in HIV-1 Subtype C.

TL;DR: High rates of virologic failure was seen when MVC was used amongst treatment experienced PLHIV infected with HIV-1 Subtype C in India.
Journal ArticleDOI

Gynecological radiotherapy in people living with human immunodeficiency virus: a semi-systematic literature review

TL;DR: The literature on cervical cancer outcomes is mixed, with some studies demonstrating that people living with HIV have inferior treatment tolerability, response rates, and survival following chemoradiotherapy, and others showing no difference, particularly in patients receiving antiretroviral therapy.
Journal ArticleDOI

Metabolic-Associated Fatty Liver Disease (MAFLD) is associated with immune activation, increased epicardial fat volume, and steatohepatitis among people with HIV in a Thai cohort.

TL;DR: In this paper , the authors investigated associations between metabolic-associated fatty liver disease (MAFLD) and immune activation, cardiovascular disease (CVD) risks including epicardial fat volume, and steatohepatitis in an Asian cohort.
Journal ArticleDOI

HIV/AIDS patients undergoing total knee arthroplasty are at higher risk of acute renal failure and transfusion and incurred higher cost: a propensity-matched database study

TL;DR: In this article , the early postoperative outcomes and complications of HIV-positive TKA patients were examined by utilizing the National Inpatient Sample (NIS) database using ICD-10-CM diagnosis codes.
Journal ArticleDOI

Mutators can drive the evolution of multi-resistance to antibiotics

TL;DR: In this paper , the authors show that bacterial populations with mutators, organisms with defects in DNA repair, readily evolve resistance to combination antibiotic treatment when there is a delay in reaching inhibitory concentrations of antibiotic.
References
More filters
Journal ArticleDOI

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement

TL;DR: Moher et al. as mentioned in this paper introduce PRISMA, an update of the QUOROM guidelines for reporting systematic reviews and meta-analyses, which is used in this paper.
Journal ArticleDOI

Bias in meta-analysis detected by a simple, graphical test

TL;DR: Funnel plots, plots of the trials' effect estimates against sample size, are skewed and asymmetrical in the presence of publication bias and other biases Funnel plot asymmetry, measured by regression analysis, predicts discordance of results when meta-analyses are compared with single large trials.
Journal ArticleDOI

Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement

TL;DR: A structured summary is provided including, as applicable, background, objectives, data sources, study eligibility criteria, participants, interventions, study appraisal and synthesis methods, results, limitations, conclusions and implications of key findings.
Related Papers (5)